CytoDyn’s Chief Medical Officer Dr. Scott Kelly to Present at Triple Negative Breast Cancer Drug Development Digital Summit 2021 on April 28
VANCOUVER, Washington, April 27, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab
(Vyrologix or PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today Scott Kelly, M.D., CytoDyn’s Chief Medical Officer will present “The Role of
Leronlimab to Treat TNBC” at the Triple Negative Breast Cancer Drug Development Digital Summit 2021 on April 28 at 2:00 pm PT / 5:00 pm ET. This exclusive digital event is not available to the
public. The event’s website can be located at www.tnbc-summit.com.
Scott Kelly, M.D., CytoDyn’s Chairman of the Board of Directors, Head of Business Development and Chief Medical Officer, commented, “We are excited about this opportunity to share with the medical and scientific communities the encouraging early indications suggested in TNBC patients treated with our monoclonal antibody, leronlimab. The FDA granted our drug with a Fast Track designation, and we are very pleased with the drug’s mechanism of action in the tumor microenvironment.”
About Leronlimab (PRO 140)
The U.S. Food and Drug Administration (FDA) granted CytoDyn Fast Track designation to explore two potential indications using leronlimab to treat HIV and metastatic cancer. The first indication is combination therapy with HAART for HIV-infected patients, and the second is for metastatic triple-negative breast cancer (mTNBC). Leronlimab is an investigational humanized IgG4 mAb that blocks CCR5, a cellular receptor important in HIV infection, tumor metastases, and other diseases, including NASH (nonalcoholic steatohepatitis). Leronlimab has been studied in 11 clinical trials involving more than 1,200 people and met its primary endpoints in a pivotal Phase 3 trial (leronlimab combined with standard antiretroviral therapies in HIV-infected treatment-experienced patients).
Leronlimab is a viral-entry inhibitor in HIV/AIDS. It masks CCR5, thus protecting healthy T cells from viral infection by blocking the predominant HIV (R5) subtype from entering those cells. Nine clinical trials have demonstrated leronlimab could significantly reduce or control HIV viral load in humans. The leronlimab antibody appears to be a powerful antiviral agent with fewer side effects and less frequent dosing requirements than currently used daily drug therapies.
Cytodyn Aktie jetzt über den Testsieger (Finanztest 11/2020) handeln, ab 0 € auf Smartbroker.de